The serum antibody responses and 5000 protective levels (PL50) of antibody were determined, using the SRH test, at one and twelve months post-vaccination in a group of student volunteers immunized with one of three dosages of a trivalent surface-antigen influenza virus vaccine, or with placebo.
INTRODUCTION
The present-day highly purified vaccines for use against influenza contain predominantly the surface haemagglutinin (HA) and neuraminidase (NA) proteins of the virus, obtained from inactivated, purified whole virus particles after disruption with detergents such as Triton N 101 (Brady & Furminger, 1976) . These vaccines are normally trivalent and include surface proteins from current A/H3N2, A/HINI and B influenza viruses. They are standardized according to the amount of HA present (Wood et al. 1977) and, as used commercially in the United Kingdom, normally contain 9-10,tg HA of each of the three component virus antigens per dose.
In recent years workers have reported on the duration of serum haemagglutination-inhibiting (HI) antibodies induced by inactivated influenza virus vaccines (Kunz et al. 1978; Potter et al. 1980; Lerman, Wright & Patil, 1980; Cate et al. 1983; Clark et al. 1983) . These studies have shown that either the mean titre of serum HI antibody, or the incidence of volunteers having protective levels of such antibody, remain relatively stable in adults six to thirteen months following immunization with subunit influenza virus vaccine (Noble et al. 1977; Kunz et al. 1978; Cate et al. 1983; Clark et al. 1983) . In children these measures of antibody level and protection appear markedly reduced at similar times following immunization (Noble et al. 1977; Potter et al. 1980; Lerman, Wright & Patil, 1980) .
In the present study, using single radial haemolysis, SRH (Oxford, Yetts & Schild, 1982; ) the response to immunization of a group of student volunteers given varying doses of a trivalent subunit influenza virus vaccine was investigated. The changes in mean antibody titre and protective antibody levels at one and twelve months following immunization to all three antigens present in the vaccine were determined.
MATERIALS AND METHODS

Virus vaccines
A commercially available, subunit, influenza virus vaccine, manufactured by Glaxo Operations (U.K.) Ltd, Speke, Liverpool, was used. This was prepared by the treatment of concentrated, purified egg-grown viruses with Triton N 101 (Brady & Furminger, 1976) . Purified HA and NA preparations from three virus strains, A/Bangkok/ 1/79 (H3N2), A/Brazil/1/78 (H IN 1) and B/Lyon/1847/79, were included in the vaccine. Three vaccine formulations were used, one containing 24 ,g each of A/Bangkok HA/0-5 ml, A/Brazil HA/0-5 ml and B/Lyon HA/0*5 ml, a total concentration of 72 jug HA/0-5 ml. The other formulations contained 12 and 6,g HA/0-5 ml ofeach virus, total concentrations of36 and 18 ,ig HA/0-5 ml respectively. A placebo (0-85 % saline) was also available.
Volunteers and study design
First-year students from the 1982 intake at the University ofSheffield volunteered to take part in the study. The design of the study and the handling of the blood samples were essentially similar to that described elsewhere (Potter et al. 1977; Jennings et al. 1981 Jennings et al. , 1984 . Inoculation of vaccine or placebo was by the deep subcutaneous route in 0 5 ml volumes under double-blind conditions. Blood samples were collected from each volunteer immediately before, and four weeks following immunization, and again, eleven to twelve months following immunization (autumn 1983) . Reactions to inoculation were assessed using a questionnaire (Jennings et al. 1978) .
Single radial haemolysis SRH tests were carried out as described previously Jennings et al. 1984; Al-Khayatt, Jennings & Potter, 1984) . Essentially, gels were prepared according to the method of Oxford, Yetts & Schild (1982 Increases in zone areas of haemolysis of 3 50 % between pre-and postimmunization sera from the same individual, tested on the same immunoplate, were taken to represent significant increases in antibody against A/H3N2 or A/HINI viruses Al-Khayatt, Jennings & Potter, 1984) . For influenza B, the equivalent increase in haemolytic zone areas was 3 45 % . Protective levels (PL 50) ofantibody have been reported to correlate with SRH zone areas of 3 25 mm2 for A/H3N2 and A/HINI viruses Al-Khayatt, Jennings & Potter, 1984) , and with SRH zone areas of 3 45 mm2 for influenza B .
Statistical methods
These were carried out using either the paired t test or the x2 test.
RESULTS
Short-term responses to immunization Incidence of reactions and antibody rises
The incidence of both local and systemic reactions, and local pain, 24 h after immunization, is shown in Table 1 . All reactions were mild and transient. The greatest incidence of both local reactions and local pain was reported for the vaccine containing the highest HA concentration. No significant systemic reaction was reported.
The incidence ofvolunteers showing significant antibody responses as determined by SRH, at four weeks following immunization to each HA component present in the vaccine, is also shown in Table 1 . For A/Bangkok, 97 % of volunteers receiving the highest, and 94 % of volunteers who received the lowest vaccine dosage responded with significant antibody rises, while 84 % of volunteers given 12 ,tg of A/Bangkok HA responded significantly. Immunization at all dosage levels also induced good SRH antibody responses to both the A/Brazil and B/Lyon HA components in the vaccine. For all three HA components in the vaccine, there was no significant difference between the dosage level of vaccine administered and the incidence of significant antibody responses as determined by SRH.
Volunteers receiving placebo showed no antibody increase to A/Brazil and A/Bangkok, but five increases to B/Lyon were observed in this group, all in volunteers with pre-immunization antibody ranging from areas of < 15 to 19 mm2 in the SRH test.
Mean antibody increases and protective levels of antibody
Immunization elicited high serum antibody levels at four weeks to all three HA components in the vaccine, with respect to both mean titres in the immunized group and the percentage of volunteers with antibody at PL50 values (Table 2) Changes in mean antibody levels and protective levels of antibody twelve months after immunization Blood specimens were not available from every volunteer twelve months following immunization. Table 3 shows both the mean SRH antibody zone areas in each volunteer group and the incidence of volunteers with SRH antibody values 3 PL 50, at both one and twelve months following immunization, for those individuals from whom serum specimens were obtained.
Mean zone areas of SRH antibody to all three virus strains had decreased significantly at twelve months compared to their values one month following immunization at all dosage levels, and this decrease was greatest for A/Bangkok antibody. Furthermore, except for the placebo group, there was a significantly greater number of decreases in antibody to A/Bangkok, as compared to either A/Brazil or B/Lyon, over this period, at all dosage levels (data not shown). Surface antigen influenza vaccine responses 93 However, with respect to each dose, mean SRH antibody zone areas to all three virus antigens remained markedly higher than their respective PL50 levels, and the percentage of individuals with SRH antibody zone areas 3 25 mm2 against A/Bangkok HA, or 3 45 mm2 against B/Lyon HA showed no significant reduction (Table 3) .
With respect to A/Brazil and the two highest dosages of vaccine used, the incidence of volunteers having SRH antibody zone areas 3 25 mm2 had actually increased (although not significantly) at twelve months, compared to the incidence at one month post-immunization. From individual paired sera it appeared that an HIN1, A/Brazil-like virus had been active amongst the volunteer group during the intervening period, as five significant increases in antibody to A/Brazil, measurable by SRH, were detected; two in volunteers who received placebo, two who received the 24 jtg dosage and one who received the 12 ,tg dosage. All five increases were in volunteers whose SRH antibody zone areas were less than the PL50 value four weeks after immunization.
DISCUSSION
The results in the present paper show that an increased antigenic mass ofinfluenza virus HA, above the 9-10 jtg present in commercially available subunit influenza virus vaccines, did notelicit significantly higherantibody levels, determined by SRH, than the dose containing 6 ,ig HA. Moreover the lowest amount of HA used, 6 ,ug, induced a high incidence ofPL 50 values ofantibody in volunteers, and this incidence remained high at twelve months post-immunization.
The vaccines used in these studies were trivalent, administered as a single dose, and the above findings apply to all three vaccine components. It is clear that no advantage is to be gained by increasing HA dosages above that recommended for commercial use. Indeed, in times of antigenic drift as at present, with respect to A/H3N2, A/HINI and B influenza viruses, the lowest vaccine dose used elicited mean SRH antibody zone areas and PL50 values at levels commensurate with protection Jennings et al. 1984;  Al-Khayatt, , against all three virus strains at both one and twelve months post-immunization. Furthermore, when sera obtained twelve months after immunization from volunteers who had received 6 ,ug HA of A/Bangkok were tested for antibody using a heterologous A/H3N2 strain, A/Philippines/82, a mean zone area of SRH antibody of 74-7 mm2 was found, and 92 % of the volunteers had A/Philippines SRH antibody zone areas above the PL50 value (unpublished observations). Although the reactions in the present study were mild and transient, a greater incidence of local reactions and pain were reported by volunteers who received the highest vaccine dose. Lower vaccine dosage would further reduce such reactions.
Previous studies in this laboratory and elsewhere (Ruben & Jackson, 1972; ) have shown that antibody responses to split or subunit vaccines may reach a plateau, or even decrease, with increasing dose. Similar findings have been reported for inactivated, whole influenza A/New Jersey/76 (HINI) vaccine (Pandemic Working Group, 1977) , although no such plateau effect was observed in a volunteer study using an adjuvanted, subunit influenza virus vaccine (Potter et al. 1977 ).
R. JENNINGS AND OTHERS
The studies described here indicate that dosages of 6 1ag HA will induce high antibody responses in primed populations (Parkman et al. 1976 ). However, during periods of antigenic shift, and in unprimed populations such as children, subunit vaccines are less effective (Jennings et al. 1981) . The persistence of high mean levels of antibody, and of high numbers of volunteers with antibody above the PL50 value at twelve months post-immunization in the present study, is thus related to the background experience of those individuals with influenza virus strains. Other workers have found antibody levels following immunization to remain stable in adults over periods ranging from five to thirteen months (Kunz et al. 1978; Cate et al. 1983 ), while in children after similar time periods following immunization marked reductions in antibody levels have been noted (Zavadova et al. 1972; Potter et al. 1980; Lerman, Wright & Patil, 1980) , suggesting that the lowest dosage of subunit vaccine used in the present study may not induce the persistence of antibody seen in adults.
A minor qualification with respect to the results in the present study is that there was evidence of influenza B virus activity at the commencement of the study, and this may have modified the antibody levels to B/Lyon seen one month following immunization. There was also evidence of HINI virus activity in the volunteer group during the period between collection of the one-and twelve-month blood specimens, which may have had some influence on the high antibody levels to this virus seen twelve months post-immunization. The infections noted at these times for both B/Lyon and A/Brazil occurred in volunteers who had SRH antibody below the PL50 values predicted by ourselves in previous studies Jennings et al. 1984; Al-Khayatt, Jennings & Potter, 1984) .
